// App-Quantinova.ai

2221 : Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Researchers

Presenter

  • Andy C. Rawstron

Principal Investigators

  • Peter Hillmen

  • Shanna Maycock

  • Nichola Webster

  • Kristian Brock

  • Rebecca H. Boucher

  • Francesca Yates

  • Rebecca Jarvis

  • Surita Dalal

  • Ruth M. de Tute

  • Paul Moss

  • Donald Macdonald

  • Piers Patten

  • Christopher Fegan

  • Andrew Pettitt

  • Christopher P. Fox

  • Adrian Bloor

  • Oonagh Sheehy

Medical Centers

  • Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, United Kingdom

  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, United Kingdom

  • Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom

  • Imperial College, London, United Kingdom

  • King's College Hospital, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • Cardiff and Vale University Health Board, Cardiff,

  • Royal Liverpool and Broardgreen University Hospital NHS Trust, Liverpool, United Kingdom

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Belfast Trust, Belfast, United Kingdom

  • St. James University Hospital, Institute of Oncology, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Ibrutinib

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • ISRCTN12695354

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved